Horizon Therapeutics Trading Halted Today; FDA Committee Meeting to Discuss Teprotumumab for Thyroid Eye Disease

Horizon Therapeutics announced that NASDAQ has halted trading of the company’s common stock, listed as HZNP. As per the FDA guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is holding a meeting today from 8 am to 4 pm ET to discuss teprotumumab, an investigational medicine for the treatment of Thyroid Eye Disease (TED).

Teprotumumab is an investigational medicine and its safety and efficacy have not been established.